Mangalam Drugs & Organics Limited (MANGALAM.NS)
INR 80.98
(-1.51%)
INR 80.98
(-1.51%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 975.81 Million INR | 22.58% |
| 2022 | 796.06 Million INR | -7.39% |
| 2021 | 859.57 Million INR | 24.37% |
| 2020 | 691.14 Million INR | 37.28% |
| 2019 | 503.44 Million INR | -18.09% |
| 2018 | 614.63 Million INR | -10.27% |
| 2017 | 684.98 Million INR | 17.74% |
| 2016 | 581.75 Million INR | 12.3% |
| 2015 | 518.01 Million INR | -26.54% |
| 2014 | 705.15 Million INR | -1.33% |
| 2013 | 714.66 Million INR | -1.85% |
| 2012 | 728.1 Million INR | 32.44% |
| 2011 | 549.74 Million INR | 8.71% |
| 2010 | 505.68 Million INR | 27.76% |
| 2009 | 395.81 Million INR | 10.72% |
| 2008 | 357.5 Million INR | 28.62% |
| 2007 | 277.94 Million INR | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | - INR | -100.0% |
| 2023 Q1 | 26.88 Million INR | -96.62% |
| 2023 Q4 | 952.61 Million INR | 1582.38% |
| 2023 Q2 | 831.88 Million INR | 2994.47% |
| 2023 Q3 | 56.62 Million INR | -93.19% |
| 2023 FY | 975.81 Million INR | 22.58% |
| 2022 Q3 | 18.99 Million INR | -97.49% |
| 2022 FY | 796.06 Million INR | -7.39% |
| 2022 Q1 | 19.54 Million INR | -97.73% |
| 2022 Q2 | 755.69 Million INR | 3766.46% |
| 2022 Q4 | 796.06 Million INR | 4091.59% |
| 2021 Q2 | 717.93 Million INR | 12031.29% |
| 2021 Q1 | 5.91 Million INR | -99.14% |
| 2021 Q3 | 30.96 Million INR | -95.69% |
| 2021 FY | 859.57 Million INR | 24.37% |
| 2021 Q4 | 859.57 Million INR | 2675.96% |
| 2020 Q4 | 691.14 Million INR | 7032.58% |
| 2020 Q3 | 9.69 Million INR | -97.95% |
| 2020 Q2 | 473.22 Million INR | 0.0% |
| 2020 FY | 691.14 Million INR | 37.28% |
| 2019 FY | 503.44 Million INR | -18.09% |
| 2019 Q4 | 503.44 Million INR | 1326.15% |
| 2019 Q1 | 14.33 Million INR | -97.67% |
| 2019 Q3 | 35.3 Million INR | -93.96% |
| 2019 Q2 | 584.57 Million INR | 3978.27% |
| 2018 Q4 | 614.63 Million INR | 2567.11% |
| 2018 FY | 614.63 Million INR | -10.27% |
| 2018 Q2 | 574.03 Million INR | 2651.32% |
| 2018 Q3 | 23.04 Million INR | -95.99% |
| 2018 Q1 | 20.86 Million INR | -96.95% |
| 2017 Q1 | 8.71 Million INR | -98.5% |
| 2017 FY | 684.98 Million INR | 17.74% |
| 2017 Q4 | 684.98 Million INR | 2954.57% |
| 2017 Q3 | 22.42 Million INR | -96.15% |
| 2017 Q2 | 582.15 Million INR | 6582.2% |
| 2016 Q3 | 11.81 Million INR | -97.75% |
| 2016 FY | 581.75 Million INR | 12.3% |
| 2016 Q1 | 7.35 Million INR | -98.58% |
| 2016 Q2 | 525.75 Million INR | 7049.28% |
| 2016 Q4 | 581.75 Million INR | 4822.2% |
| 2015 Q4 | 518.01 Million INR | 6270.91% |
| 2015 Q1 | 9.19 Million INR | -98.7% |
| 2015 Q3 | 8.13 Million INR | -98.59% |
| 2015 Q2 | 576.02 Million INR | 6163.86% |
| 2015 FY | 518.01 Million INR | -26.54% |
| 2014 Q4 | 705.15 Million INR | 14544.92% |
| 2014 Q3 | 4.81 Million INR | -99.31% |
| 2014 Q1 | 2.81 Million INR | -99.61% |
| 2014 FY | 705.15 Million INR | -1.33% |
| 2014 Q2 | 700.04 Million INR | 24768.41% |
| 2013 Q3 | 11.82 Million INR | -98.5% |
| 2013 FY | 714.66 Million INR | -1.85% |
| 2013 Q1 | 2.72 Million INR | -99.63% |
| 2013 Q2 | 787.98 Million INR | 28838.05% |
| 2013 Q4 | 714.66 Million INR | 5945.21% |
| 2012 FY | 728.1 Million INR | 32.44% |
| 2012 Q4 | 728.1 Million INR | 0.0% |
| 2011 Q4 | 549.74 Million INR | 0.0% |
| 2011 FY | 549.74 Million INR | 8.71% |
| 2010 FY | 505.68 Million INR | 27.76% |
| 2009 FY | 395.81 Million INR | 10.72% |
| 2008 FY | 357.5 Million INR | 28.62% |
| 2007 FY | 277.94 Million INR | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Aarey Drugs & Pharmaceuticals Limited | 297.57 Million INR | -227.916% |
| Aarti Drugs Limited | 5.54 Billion INR | 82.413% |
| Aarti Pharmalabs Limited | 2.61 Billion INR | 62.64% |
| Ajanta Pharma Limited | -954.9 Million INR | 202.19% |
| Alembic Limited | 66.9 Million INR | -1358.611% |
| Alkem Laboratories Limited | -1.6 Billion INR | 160.632% |
| Alembic Pharmaceuticals Limited | 3.86 Billion INR | 74.759% |
| AstraZeneca Pharma India Limited | -5.01 Billion INR | 119.468% |
| Bal Pharma Limited | 1.26 Billion INR | 22.773% |
| Biofil Chemicals and Pharmaceuticals Limited | -18.44 Million INR | 5390.095% |
| Bliss GVS Pharma Limited | -1.15 Billion INR | 184.285% |
| Brooks Laboratories Limited | 49.48 Million INR | -1871.933% |
| Bafna Pharmaceuticals Limited | 229.93 Million INR | -324.389% |
| Caplin Point Laboratories Limited | -5.5 Billion INR | 117.717% |
| Divi's Laboratories Limited | -39.77 Billion INR | 102.454% |
| Eris Lifesciences Limited | 13.8 Billion INR | 92.932% |
| Granules India Limited | 9.28 Billion INR | 89.492% |
| Ind-Swift Limited | 9.5 Billion INR | 89.738% |
| Jagsonpal Pharmaceuticals Limited | -1.38 Billion INR | 170.206% |
| J. B. Chemicals & Pharmaceuticals Limited | 2.82 Billion INR | 65.411% |
| Jubilant Pharmova Limited | 27.07 Billion INR | 96.395% |
| Kilitch Drugs (India) Limited | 120.03 Million INR | -712.912% |
| Medicamen Biotech Limited | 160.31 Million INR | -508.68% |
| Medico Remedies Limited | 78.67 Million INR | -1140.275% |
| Wockhardt Limited | 18.27 Billion INR | 94.659% |
| Orchid Pharma Limited | -1.31 Billion INR | 174.271% |
| RPG Life Sciences Limited | -364.7 Million INR | 367.565% |
| Shilpa Medicare Limited | 9.06 Billion INR | 89.241% |
| Sigachi Industries Limited | 859.94 Million INR | -13.473% |
| Solara Active Pharma Sciences Limited | 10.03 Billion INR | 90.273% |
| Unichem Laboratories Limited | 931.91 Million INR | -4.71% |
| Vaishali Pharma Limited | 119.13 Million INR | -719.08% |
| Wanbury Limited | 1.1 Billion INR | 11.761% |
| Zydus Lifesciences Limited | 3.91 Billion INR | 75.056% |
| FDC Limited | -57.75 Million INR | 1789.658% |
| Amrutanjan Health Care Limited | -248.79 Million INR | 492.22% |
| Bajaj HealthCare Limited | 3.29 Billion INR | 70.421% |
| Dr. Reddy's Laboratories Limited | 12.91 Billion INR | 92.443% |
| Glenmark Life Sciences Limited | -2.84 Billion INR | 134.327% |
| Ind-Swift Laboratories Limited | -4.15 Billion INR | 123.496% |
| Laurus Labs Limited | 24.35 Billion INR | 95.994% |
| Nectar Lifesciences Limited | 6.15 Billion INR | 84.152% |
| Par Drugs and Chemicals Limited | -366.53 Million INR | 366.223% |
| Hester Biosciences Limited | 2.29 Billion INR | 57.402% |
| Ipca Laboratories Limited | 11.41 Billion INR | 91.452% |
| Venus Remedies Limited | -267.7 Million INR | 464.517% |
| ZIM Laboratories Limited | 983.6 Million INR | 0.792% |
| Aurobindo Pharma Limited | 3.69 Billion INR | 73.579% |
| Morepen Laboratories Limited | -231.17 Million INR | 522.111% |
| Neuland Laboratories Limited | -214.05 Million INR | 555.863% |
| Sequent Scientific Limited | 4.17 Billion INR | 76.648% |
| Suven Pharmaceuticals Limited | 144.97 Million INR | -573.085% |
| Valiant Laboratories Limited | 649.9 Million INR | -50.147% |
| Windlas Biotech Limited | -273.04 Million INR | 457.388% |
| Hikal Limited | 7.96 Billion INR | 87.752% |
| Innova Captab Limited | 2.33 Billion INR | 58.187% |
| Procter & Gamble Health Limited | -2.34 Billion INR | 141.559% |
| Themis Medicare Limited | 764.96 Million INR | -27.563% |
| IOL Chemicals and Pharmaceuticals Limited | -1.1 Billion INR | 188.605% |
| Mankind Pharma Limited | -1.74 Billion INR | 155.813% |
| Glenmark Pharmaceuticals Limited | -4.28 Billion INR | 122.771% |
| Sakar Healthcare Limited | 790.93 Million INR | -23.374% |
| Albert David Limited | -278.36 Million INR | 450.546% |
| Lupin Limited | 19.38 Billion INR | 94.966% |
| Gufic Biosciences Limited | 3.19 Billion INR | 69.452% |
| Sun Pharmaceutical Industries Limited | -72.47 Billion INR | 101.347% |
| Lincoln Pharmaceuticals Limited | -127.63 Million INR | 864.514% |
| Syncom Formulations (India) Limited | 46.21 Million INR | -2011.642% |
| Piramal Enterprises Limited | 491.39 Billion INR | 99.801% |
| Torrent Pharmaceuticals Limited | 31.83 Billion INR | 96.934% |
| NATCO Pharma Limited | -5.81 Billion INR | 116.775% |
| Suven Life Sciences Limited | -1.63 Billion INR | 159.767% |
| Krebs Biochemicals & Industries Limited | 1.93 Billion INR | 49.516% |
| Strides Pharma Science Limited | 23.25 Billion INR | 95.804% |
| Indoco Remedies Limited | 6.47 Billion INR | 84.933% |
| Alpa Laboratories Limited | 35.36 Million INR | -2659.412% |
| Lasa Supergenerics Limited | 205.79 Million INR | -374.157% |
| Sun Pharma Advanced Research Company Limited | -941.8 Million INR | 203.611% |